Apricus Biosciences Announces New NexACT® Transbuccal Delivery Data Published In The International Journal Of Pharmaceutics
Apricus Biosciences, Inc. (“Apricus Bio”) (NASDAQ: APRI), announced
today that the International Journal of Pharmaceutics, a peer reviewed
journal, has published new data on the NexACT
® technology in
Apricus Biosciences, Inc. (“Apricus Bio”) (NASDAQ: APRI), announced today that the International Journal of Pharmaceutics, a peer reviewed journal, has published new data on the NexACT ® technology in their November 2010 issue, based on research conducted by, and at, the Ernest Mario School of Pharmacy, Rutgers-The State University of New Jersey in Piscataway, NJ. The article, entitled, “Enhanced in vitro Transbuccal Drug Delivery of Ondansetron HCl,” highlights NexACT enhancers’ ability to significantly improve permeation of ondansetron, a drug used to treat nausea and vomiting associated with chemotherapy and post surgery, through porcine buccal tissue. The data shows that DDAIP.HCl, one of the NexACT technology’s proprietary enhancers, provided the best improvements when compared to other enhancers (Azone, Iminosulfurane) and other technologies (iontophoresis). The highest concentration of NexACT enhancer tested (5%) did not affect the viability of the buccal cells, suggesting a safe range for clinical use. Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio, noted, “The buccal route of delivery represents an additional, new application of NexACT and potentially enables us to deliver drugs that cannot be delivered via the oral, intravenous or transdermal route.” The abstract is available at: http://www.ncbi.nlm.nih.gov/pubmed/21056647. About the NexACT Multi-Route Drug Delivery Technology NexACT utilizes biodegradable excipients, that when incorporated into drug formulations, has demonstrated the ability to help overcome the body's natural barrier properties and thereby enable rapid penetration of higher concentrations of active drug directly through the skin and major biological membranes, resulting in more effective delivery of therapies. Varying the concentration of the enhancer allows for local or systemic delivery of active drug, as desired. NexACT has shown in studies to efficiently enable the delivery of drugs across different classes and over a wide range of indications via transdermal, oral, subcutaneous, rectal and buccal routes of administration.